Avalo Therapeutics, Inc.
AVTX
$19.94
-$0.31-1.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 59.00K | -- | -- | -- | 192.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.00K | -- | -- | -- | 192.00K |
| Cost of Revenue | 8.78M | 9.99M | 10.66M | 5.91M | 5.54M |
| Gross Profit | -8.73M | -9.99M | -10.66M | -5.91M | -5.35M |
| SG&A Expenses | 6.53M | 5.58M | 5.24M | 5.55M | 5.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.80M | 19.20M | 19.32M | 14.67M | 13.50M |
| Operating Income | -19.74M | -19.20M | -19.32M | -14.67M | -13.31M |
| Income Before Tax | -13.59M | -30.61M | -20.75M | -13.14M | -35.23M |
| Income Tax Expenses | 130.00K | 11.00K | 16.00K | 8.00K | 114.00K |
| Earnings from Continuing Operations | -13.72M | -30.63M | -20.77M | -13.15M | -35.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.72M | -30.63M | -20.77M | -13.15M | -35.34M |
| EBIT | -19.74M | -19.20M | -19.32M | -14.67M | -13.31M |
| EBITDA | -19.73M | -19.14M | -19.18M | -14.53M | -13.24M |
| EPS Basic | -0.75 | -2.19 | -1.92 | -1.25 | -3.44 |
| Normalized Basic EPS | -0.47 | -1.37 | -1.20 | -0.78 | -2.15 |
| EPS Diluted | -0.75 | -2.19 | -1.92 | -1.25 | -3.44 |
| Normalized Diluted EPS | -0.47 | -1.37 | -1.20 | -0.78 | -2.15 |
| Average Basic Shares Outstanding | 18.23M | 14.00M | 10.83M | 10.51M | 10.23M |
| Average Diluted Shares Outstanding | 18.23M | 14.00M | 10.83M | 10.51M | 10.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |